Search Results 1951-1960 of 16080 for Epilepsy (Partial Onset)

1. Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer - Mayo Clinic

   ... duration of study participation, and for 3 months after the last dose of study drugs; should a woman become pregnant or suspect she is pregnant while she or ...

2. A Study of Atrial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke - Mayo Clinic

   Ability to be randomized within 3 to 120 days after stroke onset. ESUS, defined as all of the following: Stroke detected by CT or MRI that is not lacunar ...

3. Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant - Mayo Clinic

   This phase II trial studies how well pembrolizumab, lenalidomide, and dexamethasone work in treating patients with newly diagnosed multiple myeloma that are ...

4. A Study of Cardiovascular Risk Factors in Transgender Children and Youth - Mayo Clinic

   Use of glucocorticoids or anti-seizure medications in the preceding 6 months, ongoing multivitamin supplementation; Being on any hormone therapy ...

5. Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment - Mayo Clinic

   ... duration of study participation, and for 180 days after the last dose of temozolomide. Should a woman become pregnant or suspect she is pregnant while she ...

6. Glioma - Doctors and departments - Mayo Clinic

   Zimmerman, M.D.. Neurosurgeon. Phoenix, AZ. Areas of focus: Epilepsy surgery, Brain tumor surgery, Carotid endarterectomy, Trigeminal neuralgia surgery ...

7. Mepolizumab (subcutaneous route) - Mayo Clinic

   Mepolizumab injection is used with other medicines to treat severe asthma. It is given to patients whose asthma is not controlled with their current asthma ...

8. Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF) - Mayo Clinic

   The purpose of this study is to assess the safety of EXE-346 after 4 weeks of treatment in subjects with an Ileal-Pouch Anal Anastomosis (IPAA) and high bowel ...

9. Study of CG0070 Given in Combination With Pembrolizumab, in Non Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin - Mayo Clinic

   Study of CG0070 Given in Combination With Pembrolizumab, in Non Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin · Share · Facebook ...

10. Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS - Mayo Clinic

    Disease duration from symptom onset (defined by first muscle weakness or dysarthria) 12-48 months at the time of visit 1 (baseline). Able to perform supine ...